DSNKY Stock, Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Information

Founded on September , through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan Olmetec , launched in by Sankyo and now available in more than countries around the world the antiplatelet agent prasugrel Efient , launched in for patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI and edoxaban Lixiana , the first available factor Xa inhibitor in Japan, which launched in to help prevent venous thromboembolism VTE .